On May 14, 2026, at the 38th Annual Meeting of the International Society for Gynecologic Endoscopy (ISGE) held in Algiers, North Africa, the "Alliance of Tumor-Fertility" (Alliance of Tumor-Fertility) was led by Professor Wang Jianliu of Peking University People's Hospital and jointly initiated by top experts from many countries around the world Preservation, abbreviated as ATFP) was officially established. This marks a new stage of global multi-country cooperation in the field of reproductive tumors, escorting the fertility dreams of young cancer patients around the world.

On May 12, 2026, a major health policy initiative published online in The Lancet announced that after an unprecedented and rigorous multi-step global consensus process, "Polycystic Ovarian Syndrome (PCOS)", which affects more than 170 million women worldwide, will be officially renamed "Polyendocrine Ovarian Syndrome (PMOS)" Metabolic Ovarian Syndrome）” 。

On May 8, the 15th Asia Pacific Initiative on Reproduction (ASPIRE) Annual Meeting opened in Beijing. At the opening ceremony, Professor Chen Zijiang, academician of the Chinese Academy of Sciences, chair professor of Shandong University, and dean of the Institute of Women's and Child and Reproductive Health of Shandong University, was awarded the highest honor of the society - Honorary Membership. Only one ASPIRE Honorary Member is selected each year to highlight their high scarcity and honorary value.

Recently, Professor Yin Chenghong's team from Beijing Obstetrics AND Gynecology Hospital Affiliated to Capital Medical University published a paper entitled "SESN2 suppresses ferroptosis in polycystic ovary syndrome by maintaining PRDX6 K209 lactylation" in the journal "FREE RADICAL BIOLOGY AND MEDICINE", a journal in the Q1 area of biology. This study proposed for the first time a new regulatory axis of "SESN2-PRDX6 lactation modification" and elucidated the molecular mechanism by which PRDX6 expression regulates ovarian function. Polycystic ovary syndrome (PCOS) affects 8-10% of women of childbearing age worldwide and is the leading cause of ovulation-dysfunctional infertility. Recently, a study published in Free Radical Biology and Medicine revealed a new "SESN2-PRDX6 lactylate" signaling axis, which acts like an "invisible guardian" to inhibit ferroptosis in ovarian granulosa cells through a protein modification called "lactoylation", thereby protecting ovarian function. This discovery opens up a promising new direction for the treatment of PCOS.

The research on the microecology of the reproductive tract at the Obstetrics and Gynecology Center of Peking University Shenzhen Hospital continues to make original breakthroughs. Dr. Dai Wenkui was invited to give a keynote speech at the IPVS conference held in Athens, Greece in October 2026, becoming the only invited keynote speaker in Asia, highlighting the international influence of the Chinese team in this field. Recently, the International Papillomavirus Society Annual Meeting (IPVS 2026) announced the list of keynote speakers, and Dr. Dai Wenkui, a core expert in reproductive system disease research at the Obstetrics and Gynecology Center of Peking University Shenzhen Hospital, was invited to give a keynote speech. The conference will be held in Athens, Greece in October 2026, and Dr. Dai Wenkui is the only invited keynote speaker in Asia. This invitation reflects the high recognition of the international academic community for the research work of the female reproductive tract microecology of the Obstetrics and Gynecology Center of Peking University Shenzhen Hospital.

Embryo quality is a core determinant of clinical outcomes in assisted reproductive technology (ART). Poor embryo quality and repeated implantation failure remain critical challenges in reproductive medicine, with a lack of effective clinical interventions currently available. Recently, a prospective clinical study led by Professor Hao Guimin's team at the Second Hospital of Hebei Medical University was officially published in Frontiers in Cell and Developmental Biology (IF=4.3). The study confirms that intervention with the innovative compound Reco18 can significantly improve embryological parameters and clinical pregnancy rates in patients with a history of IVF/ICSI failure and poor embryo quality. It provides high-level clinical evidence for fertility restoration in populations of advanced maternal age and those with repeated ART failure.

Many people don't know that diet during pregnancy preparation and early pregnancy is not a trivial matter. A prospective study of 855 couples preparing for pregnancy, recently published in Human Reproduction, tells us with real data: the more ultra-processed foods you eat, the more difficult it is to get pregnant and the slower the embryo grows.

It is reported that the British company Verso Biosense is developing an intrauterine device with sensors that can collect environmental data inside the uterus in real time, providing new technical means for fertility research and women's health care. The device is similar in appearance to a traditional IUD for contraception, but has a tiny sensor integrated inside. These sensors continuously monitor metrics such as uterine temperature and oxygen content and transmit the data wirelessly for researchers to analyze. The researchers hope that this device will help uncover the mysteries of one of the most understood organs in medicine, the uterus.

Will the risk of stillbirth increase if you encounter extreme heat during pregnancy? This issue is becoming more and more concerned in the context of intensifying climate change. A prospective longitudinal study based on a Chinese birth cohort study involving more than 240,000 pregnant women gave a more refined answer: the key window period for high temperature exposure to increase the risk of stillbirth is not the entire pregnancy, but is concentrated at 32-36 weeks of gestation, especially at 35 weeks of gestation; What is even more surprising is that the high humidity environment did not exacerbate the harm of high temperatures, but showed an antagonistic effect - the risk of stillbirth in dry heat conditions was much higher than in humid heat conditions. This finding has important value for obstetric clinical guidance and public health policy formulation. The latest research results of Professor Liu Ruixia's team from Beijing Obstetrics and Gynecology Hospital Affiliated to Capital Medical University were published in the authoritative journal "Environmental Research" in the field of environment. Based on the Chinese birth cohort study, the research team covered 334,924 pregnant women recruited from 52 hospitals in Chinese mainland between February 2018 and December 2022, and finally included 244,204 pregnancies after exclusion, including 243,262 live births and 942 stillbirths. Stillbirth is defined as a gestational age of ≥ 20 weeks and no signs of life at birth, excluding termination of pregnancy due to fetal abnormalities.

Recently, the research team led by Professor Chenghong Yin at Beijing Obstetrics and Gynecology Hospital, Capital Medical University, published a paper titled “CDH4/UBA1/RBMX axis promotes polycystic ovary syndrome progression through YAP1 activation” in the CAS Q1 journal Cellular & Molecular Biology Letters. This study confirms that abnormal proliferation of ovarian granulosa cells promotes ovarian dysfunction in polycystic ovary syndrome (PCOS) and reveals for the first time the molecular mechanism by which the CDH4/UBA1/RBMX axis regulates abnormal granulosa cell proliferation. In PCOS patients, reduced apoptosis and abnormal proliferation of ovarian granulosa cells are core causes of ovulatory dysfunction and infertility. CDH4 acts as a “molecular switch” that is abnormally highly expressed in the ovarian granulosa cells of PCOS patients. By manipulating a novel UBA1-RBMX-YAP1 signaling axis, it not only exacerbates ovarian inflammation but also blocks normal apoptosis of granulosa cells, providing a highly promising new therapeutic target for PCOS.